

# Neepa Yogesh Choksi, Ph.D.

SUPERVISING SCIENTIST

## CONTACT INFORMATION

---

ToxStrategies, A BlueRidge Life Sciences Company  
600 Park Offices Drive, Suite 300  
PO Box 13965  
Durham, NC 27709  
Phone (919) 599-5960  
[nchoksi@toxstrategies.com](mailto:nchoksi@toxstrategies.com)

## PROFESSIONAL PROFILE

---

Dr. Neepa Choksi is a toxicologist in ToxStrategies' Health Sciences practice. She has three decades of experience in the private and governmental sectors, as well as academia. Her broad expertise includes assessing quantitative structure-activity relationship (QSAR) outcomes, conducting comprehensive literature and scientific evaluations, synthesizing results from diverse literature sources and internal documents, and preparing reports for regulatory submission and internal client information, as well as articles for peer-reviewed publication. She has a depth of knowledge in the fields of pharmacology, toxicology, and chemistry.

Dr. Choksi has experience in evaluation and application of New Approach Methodologies (NAMs). She has extensive experience in application of read-across and bridging frameworks for research and regulatory needs. Dr. Choksi also has knowledge in using and assessing predictions from QSAR platforms (both publicly available and subscription-based software). Dr. Choksi has experience with literature review software (e.g., DistillerSR, SysRev), collaborating with multiple stakeholders to define project scopes and objectives, managing diverse teams of scientists to assess human health hazards of environmental and chemical agents, facilitating effective communication during all project phases, and preparing high-quality deliverables.

Dr. Choksi's occupational experience includes serving as a Principal Toxicologist for a private-sector laboratory in Research Triangle Park, North Carolina, as well as time as a Science Policy Fellow with the National Institute of Environmental Health Sciences' (NIEHS's) Office of Policy, Planning, and Evaluation, with US EPA's Office of Solid Waste and Emergency Response (OSWER). She has also worked as a registered patent agent for a patent-law firm in New York. As a Postdoctoral Research Fellow (Mount Sinai Medical Center, Department of Psychiatry, New York), she studied the causative factors of familial early-onset Alzheimer's disease using advanced molecular and cellular biological techniques, and also managed the laboratory's radiation use and maintained compliance with health and safety regulations.

---

## EDUCATION AND DEGREES EARNED

1998 Ph.D., Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill  
1992 B.S., Chemistry, Bucknell University, Lewisburg, PA

---

## PROFESSIONAL HONORS/AWARDS

2022 Society of Toxicology, *In Vitro* and Alternative Methods Specialty Section, article selected for Best Paper Award (see Clippinger et al., 2021, below)  
2021 Society of Toxicology, Ocular Toxicity Specialty Section, article selected as Paper of the Year (see Choksi et al., 2021, below)  
2021 Society of Toxicology, contributor to continuing education course, "Rapid chemical assessments using open computational models"

---

## PROFESSIONAL ASSOCIATIONS

1992–Present American Chemical Society  
2004–Present Society of Toxicology (SOT), *In Vitro* and Alternative Methods Specialty Section

---

## SELECTED PROFESSIONAL EXPERIENCE

### *Toxicology*

Served as the project lead at the National Toxicology Program Interagency Center for the Evaluation of Alternative Methods (NICEATM) for efforts focused on evaluation of non-animal eye irritation methods. Projects included leading validation studies, developing defined approaches, and assessing the variability of *in vivo* test methods.

Proficient in gathering data from toxicological and literature databases (e.g., CompTox Dashboard, PubMed, SciFinder, and Causaly) to support client projects and needs.

Led support contract review of chemicals nominated for *in vivo* testing to the National Toxicology Program. Supervised and conducted literature searches in free and fee-based programs; reviewed data and literature related to human exposure potential, routes of exposure, metabolism, genetic toxicity, and *in vivo* toxicity; and synthesized information into a document that was used in the NTP decision-making process.

Utilized a variety of freely available and commercial (Q)SAR platforms (e.g., ToxTree, CASEUltra, DEREK) to address client queries regarding chemical toxicity.

Supported development of the NICEATM Integrated Chemical Environment database by providing expert review of all ocular and dermal irritation data-set information to ensure that relevant meta-data were present for user need and use.

Supported development of *in silico* toxicity models through identification of literature and development of data sets for use in model development.

### Project Management

Developed and managed a program to handle (Q)SAR requests for returning and new clients. Assisted in quote preparation, project resources, and deliverable submission while meeting budgetary constraints.

Managed up to five junior and mid-level scientific staff to ensure that all projects remained on schedule.

### MANUSCRIPTS

---

**Choksi N**, McMillan D, Schmitt D, Doepker C, Henderson RG. 2026. Demonstration of safety for rice bran wax and sunflower wax based on bridging to other naturally derived waxes used in food. *Regul Toxicol Pharmacol* 165(Feb):105990; doi: [10.1016/j.yrph.2025.105990](https://doi.org/10.1016/j.yrph.2025.105990).

Doepker C, Franzen A, Brorby G, Brown L, **Choksi N**, East A, Wikoff D. 2026. Smoke flavoring—A case study demonstrating the value of using benefit-risk analysis for foods (BRAFO) to provide transparency for risk management decisions. *Regul Toxicol Pharmacol* 106033. Advance online publication Jan. 21, 2026; doi: [10.1016/j.yrph.2026.106033](https://doi.org/10.1016/j.yrph.2026.106033).

Borghoff SJ, Rivera B, Fitch S, Buerger AN, **Choksi N**, Franzen A, Vincent MJ, Covington T, Bus J, Rushton E, Lea IA. 2025. Systematic evaluation of the evidence base on methyl *tert*-butyl ether supporting a lack of concern for carcinogenic hazard in human based on animal cancer studies and mechanistic data. *Curr Res Toxicol* 8:100224; doi: [10.1016/j.crtox.2025.100224](https://doi.org/10.1016/j.crtox.2025.100224).

Rivera BN, Lea IA, Fitch S, **Choksi N**, Franzen A, Bus J, Rushton E, Borghoff SJ. 2025. Systematic evaluation of the evidence base on ethyl *tert*-butyl ether and *tert*-butyl alcohol for carcinogenic potential in humans: Lack of concern based on animal cancer studies and mechanistic data. *Curr Res Tox* 10(Nov 10):100270; doi: [10.1016/j.crtox.2025.100270](https://doi.org/10.1016/j.crtox.2025.100270).

Doepker C, Rabert C, Heard P, Dubnicka T, **Choksi N**, Eapen A. 2024. An investigation of the genotoxic potential of a well-characterized yerba mate extract. *Toxicol Rep* 12(June):477–484; <https://doi.org/10.1016/j.toxrep.2024.04.007>.

Mihalchik AL, **Choksi NY**, Roe AL, Wisser M, Whitaker K, Seibert D, Deore M, Pavlick L, Wikoff DS. 2024. Safety evaluation of 8 drug degradants present in over-the-counter cough and cold medications. *Regul Toxicol Pharmacol* 149(May):105621; doi: [10.1016/j.yrph.2024.105621](https://doi.org/10.1016/j.yrph.2024.105621).

Borghoff SJ, Cohen SS, Jiang X, Lea IA, Klaren WD, Chappell GA, Britt JK, Rivera BN, **Choksi NY**, Wikoff DS. 2023. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame. *Food Chem Toxicol* 172(Feb):113549; doi: [10.1016/j.fct.2022.113549](https://doi.org/10.1016/j.fct.2022.113549).

Sedykh A, **Choksi NY**, Allen DG, Casey WM, Shah R, Kleinstreuer NC. 2022. Mixtures—Inclusive in silico models of ocular toxicity based on United States and international hazard categories. *Chem Res Toxicol* 35(6):992–1000; doi: [10.1021/acs.chemrestox.1c00443](https://doi.org/10.1021/acs.chemrestox.1c00443).

**Choksi NY**, Daniel AB, Allen DG, Clippinger AJ, Kleinstreuer NC. 2021. Prospective and retrospective evaluation of the eye irritation potential of agrochemical formulations. Research Triangle Park, NC: National Toxicology Program. NICEATM Report 01.

Clippinger AJ, Raabe HA, Allen DG, **Choksi N**, van der Zalm A, Kleinstreuer N, Barroso J, Lowit AB. 2021. Human-relevant approaches to assess eye corrosion/irritation potential of agrochemical formulations. *Cutan Ocul Toxicol* 40(2):145–167; doi: [10.1080/15569527.2021.1910291](https://doi.org/10.1080/15569527.2021.1910291).

Rooney JP, **Choksi NY**, Ceger P, Daniel AB, Truax J, Allen D, Kleinstreuer N 2021. Analysis of variability in in vivo rabbit skin irritation assay results. *Regul Toxicol Pharmacol* 122(June):104920; doi: [10.1016/j.yrph.2021.104920](https://doi.org/10.1016/j.yrph.2021.104920).

**Choksi N**, Lebrun S, Nguyen M, Daniel A, DeGeorge G, Willoughby J, et al. 2020. Validation of the OptiSafe Eye Irritation Test. *Cutan Ocul Toxicol* 39(3):180–192; doi: [10.1080/15569527.2020.1787431](https://doi.org/10.1080/15569527.2020.1787431).

Howard AS, **Choksi NY**. 2020. Evaluation of two in silico programs for predicting mutagenicity and carcinogenicity potential for 4-methylimidazole (4-Mel) and known metabolites. *Toxicol Mech Methods* 30(4):246–256; doi: [10.1080/15376516.2019.1709237](https://doi.org/10.1080/15376516.2019.1709237).

**Choksi NY**, Truax J, Layton A, Matheson J, Mattie D, Varney T, et al. 2019. United States regulatory requirements for skin and eye irritation testing. *Cutan Ocul Toxicol* 38(2):141–155; doi: [10.1080/15569527.2018.1540494](https://doi.org/10.1080/15569527.2018.1540494).

Casey WM, Chang X, Allen DG, Ceger PC, **Choksi NY**, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. *Environ Health Perspect* 126(9):97001; doi: [10.1289/EHP1655](https://doi.org/10.1289/EHP1655).

Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer ... **Choksi N**, et al. 2018. In vitro to in vivo extrapolation for high throughput prioritization and decision making. *Toxicol In Vitro* 47(March):213–227; doi: [10.1016/j.tiv.2017.11.016](https://doi.org/10.1016/j.tiv.2017.11.016).

Strickland J, Zang Q, Paris M, Lehmann DM, Allen D, **Choksi N**, et al. 2017. Multivariate models for prediction of human skin sensitization hazard. *J Appl Toxicol* 37(3):347–360; doi: [10.1002/jat.3366](https://doi.org/10.1002/jat.3366).

Strickland J, Zang Q, Kleinstreuer N, Paris M, Lehmann DM, **Choksi N**, et al. 2016. Integrated decision strategies for skin sensitization hazard. *J Appl Toxicol* 36(9):1150–1162; doi: [10.1002/jat.3281](https://doi.org/10.1002/jat.3281).

Hamernik K, Eskes C, Merrill J, **Choksi N**, Allen D, Truax J, et al. 2006. ICCVAM-NICEATM-ECVAM symposium on mechanisms of chemically-induced ocular injury and recovery: Current understanding and knowledge gaps. *ALTEX* 23(Spec Iss 2):321–323.

Jahnke GD, **Choksi NY**, Moore JA, Shelby MD. 2004. Thyroid toxicants: Assessing reproductive health effects. *Environ Health Perspect* 112(3):363–368; doi: [10.1289/ehp.6637](https://doi.org/10.1289/ehp.6637).

**Choksi NY**, Jahnke GD, St Hilaire C, Shelby MD. 2003. Role of thyroid hormones in human and laboratory animal reproductive health. *Birth Defects Res B* 68(6):479–491; doi: [10.1210/er.2015-1106](https://doi.org/10.1210/er.2015-1106).

Booth RG, Moniri NH, Bakker RA, **Choksi NY**, Nix WB, Timmerman H, Leurs R. 2002. A novel phenylaminotetralin radioligand reveals a sub-population of histamine H1 receptors. *J Pharmacol Exper Ther* 302(1):328–336; doi: [10.1124/jpet.302.1.328](https://doi.org/10.1124/jpet.302.1.328).

**Choksi NY**, Nix WB, Wyrick SD, Booth RG. 2000. A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain. *Brain Res* 852(1):151–160; doi: [10.1016/s0006-8993\(99\)02228-3](https://doi.org/10.1016/s0006-8993(99)02228-3).

Kodavanti PR, Derr-Yellin EC, Mundy WR, Shafer TJ, Herr DW Barone S, **Choksi, NY**, MacPhail RC, Tilson HA. 1998. Repeated exposure of Aroclor 1254 causes brain region-specific changes in intracellular Ca<sup>2+</sup> buffering and protein kinase C activity in the absence of changes in tyrosine hydroxylase. *Toxicol Appl Pharmacol* 153(2):186–198; doi: [10.1006/taap.1998.8533](https://doi.org/10.1006/taap.1998.8533).

**Choksi NY**, Hussain A, Booth RG. 1996. 2-Phenylaminoadenosine stimulates adenylyl cyclase activity and dopamine biosynthesis through an A2 receptor mediated mechanism. *Brain Res* 761(1):151–155; doi: [10.1016/s0006-8993\(97\)00445-9](https://doi.org/10.1016/s0006-8993(97)00445-9).

**Choksi NY**, Kodavanti PRS, Tilson H, Booth RG. 1996. Effects of polychlorinated biphenyls on brain tyrosine hydroxylase activity in rats. *Fundam Appl Toxicol* 39(1):76–80; doi: [10.1006/faat.1997.2351](https://doi.org/10.1006/faat.1997.2351).

---

## P R E S E N T A T I O N S

---

Borghoff SJ, Rivera BN, Fitch S, Buerger A, **Choksi N**, Franzen A, Bus J, Rushton EK, Lea I. Systematic evaluation of the evidence base on methyl tert-butyl ether for carcinogenic potential in humans; Low concern based on animal cancer studies and mechanistic data. Abstract 4702, Society of Toxicology 64<sup>th</sup> Annual Meeting, Orlando, FL, March 2025.

Rivera BN, Lea IA, Fitch S, **Choksi N**, Franzen A, Bus J, Rushton EK, Borghoff SJ. Systematic evaluation of the evidence base on ethyl tert-butyl ether and tert-butyl alcohol for carcinogenic potential in humans: Low concern based on animal cancer studies and mechanistic data. Abstract 4697, Society of Toxicology 64<sup>th</sup> Annual Meeting, Orlando, FL, March 2025.

Wikoff D, Fitch S, Vincent M, Southall MD, Atillasoy E, Weinstein RD, Ejaz SD, Rhoden JD, **Choksi N**. Biological plausibility assessment of acetaminophen and occurrence of developmental neurological outcomes in humans. Abstract 4768, Society of Toxicology 64<sup>th</sup> Annual Meeting, Orlando, FL, March 2025.

Lynn SG, Lea IA, Urban J, Borghoff SJ, Wikoff D, Fitch S, Perry C, **Choksi N**, Britt J, Heintz M, Klaren W, et al. Development and application of systematic approach to inventory and interrogate thyroid hormone network information. Abstract 4357, Society of Toxicology 63<sup>rd</sup> Annual Meeting, Salt Lake City, UT, March 2024.

**Choksi NY**, Fitch S, Harris MA, Thompson CM, Wikoff DS. Reliability assessment of guideline-based studies using systematic review critical appraisal tools. Poster presented at Society of Toxicology 62<sup>nd</sup> Annual Meeting, Nashville, TN, March 2023.

Mihalchik AL, **Choksi NY**, Wood ML. Toward best practices for read-across in evaluation of drug impurities, extractable, and leachable compounds. Poster presented at Society of Toxicology 62<sup>nd</sup> Annual Meeting, Nashville, TN, March 2023.

Mihalchik AL, **Choksi NY**, Lea I, Wood ML. Modern strategies to evaluate drug impurities. Session presented at Society of Toxicology 62<sup>nd</sup> Annual Meeting, Nashville, TN, March 2023.

Mansouri K, Martin T, **Choksi N**, Chang X, Allen D, Williams A, Kleinstreuer N, OPERA, an open-source and open-data suite of QSAR models. Oral presentation at American Chemical Society fall meeting, Chicago, IL, August 2022.

**Choksi N**, Latorre A, Pais M, Murata R, Catalano S, Aguilera M, Pires J, Ogasawara M, Habe P, Perjessy G, Allen D. Testing strategies for evaluation of eye irritation potential of agrochemical formations as an alternative to animal testing. Poster presented at XXII Brazilian Congress of Toxicology, Balneario Camboriu, Brazil, May 2022.

Rooney J, Abedini J, Bell S, Chang X, Cook B, Ceger P, **Choksi N**, et al. Building confidence in alternative methods through ICE. Poster presented at Society of Toxicology 61<sup>st</sup> Annual Meeting, San Diego, CA, March 2022.

Catalano S, **Choksi N**, Corvaro M, Kolle S, Stinchcombe S, Latorre A, et al. Reducing animal use for eye irritation testing of agrochemicals in Brazil. Poster presented at Society of Toxicology 61<sup>st</sup> Annual Meeting, San Diego, CA, March 2022.

Allen DG, Rooney J, To K, **Choksi N**, Ceger P, Daniel A, et al. Variability in reference test method data and the impact on NAM evaluations. Poster presented at Society of Toxicology 61<sup>st</sup> Annual Meeting, San Diego, CA, March 2022.

**Choksi N**. Identifying data on your chemical. Continuing Education Course: Rapid Chemical Assessment Using Open Computational Methods, Presented at Society of Toxicology 60<sup>th</sup> Annual Meeting, Virtual, March 2021.

Ceger P, Allen DG, **Choksi N**, Daniel A, Eckel W, Hamm J, et al. Retrospective evaluation of the acute fish toxicity test for pesticide registration. Poster presented at Society of Toxicology 60<sup>th</sup> Annual Meeting, Virtual, March 2021.

Kandarova H, Raabe H, Hilberer A, **Choksi N**, Allen D. Retrospective review on in vitro phototoxicity data generated in 3D skin models to support the development of new OECD test guideline. Poster presented at Society of Toxicology 60<sup>th</sup> Annual Meeting, Virtual, March 2021.

Rooney JP, **Choksi N**, Ceger P, Daniel AB, Truax J, Allen DG, Kleinstreuer NC. Variability in the rabbit skin irritation assay. Poster presented at Society of Toxicology 60<sup>th</sup> Annual Meeting, Virtual, March 2021.

**Choksi N**, Clippinger AJ, Gehen S, Corvaro M, Kolle SN, Bentley K, et al. Developing a defined approach for eye irritation testing. Poster presented at Society of Toxicology 59<sup>th</sup> Annual Meeting, Virtual, March–June 2020.

Lebrun SJ, **Choksi N**, Daniel A, Allen D, Casey W. Prevalidation of the OptiSafe ocular irritation assay for the detection of ocular corrosives. Poster presented at Society of Toxicology 58<sup>th</sup> Annual Meeting, Baltimore, MD, March 2019.

Swartz C, Howard AS, **Choksi N**, Rauer A, Allen DG, Recio L, Karmaus AL. An integrated approach for animal-free genotoxicity testing: In vitro and in silico evaluation and mode-of-action classification. Poster presented at Society of Toxicology 58<sup>th</sup> Annual Meeting, Baltimore, MD, March 2019.

Sedykh A, **Choksi N**, Allen D, Kleinstreuer N, Casey W, Shah, R. Mixture-based modeling of chemical ocular toxicity based on the US EPA hazard categories. Poster presented at Society of Toxicology 58<sup>th</sup> Annual Meeting, Baltimore, MD, March 2019.

**Choksi N**, Clippinger AJ, Gehen S, Corvaro M, Ng S, Kolle SNE, van Cott A, et al. Defined approach for detection of eye irritants and corrosives for pesticide formulations. Poster presented at Society of Toxicology 58<sup>th</sup> Annual Meeting, Baltimore, MD, March 2019.

**Choksi N**, Daniel A, Lebrun S, Nguyen M, DeGeorge G, Willoughby JA, et al. Performance of the OptiSafe ocular irritation assay in a three-laboratory validation study. Poster presented at Society of Toxicology 57<sup>th</sup> Annual Meeting, San Antonio, TX, March 2018.

Ceger P, **Choksi N**, Hamm J, Truax J, Daniel A, Allen D, et al. Development of a curated database of in vivo developmental toxicity data. Poster presented at Society of Toxicology 56<sup>th</sup> Annual Meeting, Baltimore, MD, March 2017.

Strickland J, Zang Q, Paris M, Lehman DM, Kleinstreuer N, Allen D, **Choksi N**, et al. Multivariate models for prediction of human skin sensitization hazard. Poster presented at Society of Toxicology 55<sup>th</sup> Annual Meeting, New Orleans, LA, March 2016.

Chang X, Kleinstreuer N, Ceger P, **Choksi N**, Hsieh J.-H, Wetmore BA et al. In vitro to in vivo extrapolation for estrogenic activity of environmental chemicals. Poster presented at Society of Toxicology 55<sup>th</sup> Annual Meeting, New Orleans, LA, March 2016.

Yang C, Casey W, **Choksi N**, Ceger P, Kleinstreuer N, Allen D, et al. An in vitro test method for screening potential androgenic agonists and antagonists in mda-kb2 cells. Poster presented at Society of Toxicology 55<sup>th</sup> Annual Meeting, New Orleans, LA, March 2016.

Auerbach SS, **Choksi NY**, Ferguson S, Hsieh J, Svoboda DL, Myatt GJ, et al. HTS and SAR analysis of chemicals from the elk river spill. Poster presented at Society of Toxicology 54<sup>th</sup> Annual Meeting, San Diego, CA, March 2015.

Strickland J, **Choksi NY**, Allen DG, Casey W. In silico predictions of skin sensitization using OECD QSAR toolbox. Poster presented at Society of Toxicology 54<sup>th</sup> Annual Meeting, San Diego, CA, March 2015.

Chang X, Kleinstreuer N, Ceger P, **Choksi NY**, Hsieh J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54<sup>th</sup> Annual Meeting, San Diego, CA, March 2015.

Strickland J, Zang Q, Paris M, Kleinstreuer N, Lehmann DM, Allen D, **Choksi N**, et al. Machine learning approaches for predicting human skin sensitization hazard. Poster presented at FutureToxIII, Baltimore, MD, November 2015.

Stokes W, Allen D, Burns T, **Choksi N**, Matheson, J, Jacobs, Tice, R. Performance characteristics of the local lymph node assay (llna) limit dose procedure. Poster presented at Society of Toxicology 47<sup>th</sup> Annual Meeting, Seattle, WA, March 2008.

Tice R, Allen D, **Choksi N**, Truax J, Stokes W. Relationship between adverse ocular effects and their reversibility. Poster presented at the 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan, August 2007.

**Choksi N**, Haseman J, Truax J, Wnorowski G, Merkel D, Stokes W. Topical anesthetic pre-treatment in the Draize eye test: Impact on hazard classification. Poster presented at the 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan, August 2007.

Kulpa-Eddy J, Jacobs A, Halder M, Burns T, **Choksi N**, Allen D, et al. Alternatives to the mouse LD50 assay for botulinum toxin testing: An ICCVAM/NICEATM/ECVAM sponsored workshop. Poster presented at the 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan, August 2007.

**Choksi NY**, Haseman JK, Truax JF, Charles JM, Wnorowski G, Merkel D, Stokes WS. Effect of topical anesthetic pretreatment on in vivo ocular irritation hazard classification. Poster presented at Society of Toxicology 46<sup>th</sup> Annual Meeting, Charlotte, NC, March 2007.

Kulpa-Eddy J, Jacobs AC, Halder M, Burns TA, **Choksi NY**, Allen DG, Tice RR, Stokes WS. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)/National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)/European Centre for the Validation of Alternative Methods (ECVAM) workshop on alternative methods to refine, reduce, and replace the mouse LD50 assay for botulinum toxin testing. Poster presented at Society of Toxicology 46<sup>th</sup> Annual Meeting, Charlotte, NC, March 2007.

Allen D, Blackard B, **Choksi N**, Truax J, Tice R, Stokes W. Reference substances for the validation of in vitro ocular toxicity test methods for the evaluation of ocular corrosives and severe irritants. Poster presented at Society of Toxicology Annual Meeting, 45<sup>th</sup> San Diego, CA, March 2006.

**Choksi NY**, Haseman J, Allen DG, Tice RR, Stokes WS. Estimated likelihood for under- and over-classification for a sequential Draize rabbit eye test. Poster presented at Society of Toxicology 45<sup>th</sup> Annual Meeting, San Diego, CA, March 2006.

Stokes WS, **Choksi NY**, Allen DG, Truax JF, Tice RR. Comparative performance of four in vitro test methods for the classification of ocular corrosives and severe irritants. Poster presented at Society of Toxicology 45<sup>th</sup> Annual Meeting, San Diego, CA, March 2006.

Tice RR, Allen DG, **Choksi NY**, Truax JF, Stokes WS. Evaluation of the relationship between in vivo rabbit eye test scores and their reversibility. Poster presented at Society of Toxicology 45<sup>th</sup> Annual Meeting, San Diego, CA, March 2006.

Eskes C, Allen DG, Tice RR, **Choksi NY**, Truax JF, Chambers W, Stokes WS, Schechtman LM. In vitro models for ocular injury: Current and potential biomarkers. Presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Stokes WS, Chambers W, Bonner M, Allen DG, Tice RR, **Choksi NY**, et al. In vivo models of ocular injury and recovery: Current and potential biomarkers to support development and validation of predictive in vitro models. Presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Stokes WS, **Choksi NY**, Allen DG, Truax JF, Tice RR, Eskes C, et al. Mechanisms of chemically-induced ocular injury and recovery: Current understanding and knowledge gaps. Presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

**Choksi NY**, Allen DG, Blackard BC, Inhof CJ, Tice RR, Truax JF, Stokes WS. Performance of the Hen's Egg Test - Chorioallantoic Membrane (HET-CAM) test method in detecting ocular corrosives and severe irritants. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Tice RR, Allen DG, Blackard BC, **Choksi NY**, Inhof CJ, Truax JF, Stokes WS. Performance of the Bovine Corneal Opacity and Permeability (BCOP) test method in detecting ocular corrosives and severe irritants. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Truax JF, Allen DG, Blackard BC, **Choksi NY**, Inhof CJ, Tice R, Stokes WS. Performance of the Isolated Rabbit Eye (IRE) test method in detecting ocular corrosives and severe irritants. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Allen DG, Blackard BC, **Choksi NY**, Inhof CJ, Truax JF, Tice RR, Stokes WS. Performance of the Isolated Chicken Eye (ICE) test method in detecting ocular corrosives and severe irritants. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Allen DG, Blackard BC, **Choksi NY**, Truax JF, Tice RR, Stokes WS, et al. Proposed reference substances for optimization and validation studies with in vitro ocular test methods. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Haseman J, Tice RR, Allen DG, **Choksi NY**, Stokes WS. Estimated under- and over-classification rates for a 1-3 rabbit sequential Draize rabbit eye test. Poster presented at the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, August 2005.

Haseman JH, **Choksi NY**, Inhof CJ, Truax JF, Tice RR, Stokes WS. The performance characteristics of the in vivo rabbit eye test. Poster presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

**Choksi NY**. Current in vitro models of ocular injury and recovery: Vascular assays. Presented at the ICCVAM/NICEATM/ECVAM Ocular Toxicity Scientific Symposium on Mechanisms of Chemically-Induced Ocular Injury and Recovery, May 2005.

**Choksi NY**, Allen DG, Inhof CJ, Truax JF, Tice RR, Stokes WS. Performance of BCOP, IRE, ICE, and HET-CAM in detecting substances that induce severe irritation and irreversible ocular damage. Presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

**Choksi NY**, Allen DG, Inhof CJ, Truax JF, Tice RR, Stokes WS. Validation status of the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) test method. Poster presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

Inhof CJ, **Choksi NY**, Allen DG, Truax JF, Tice RR, Stokes WS. Validation status of the Bovine Corneal Opacity and Permeability (BCOP) test method. Poster presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

Allen DG, **Choksi NY**, Inhof CJ, Truax JF, Tice RR, Stokes WS. Validation status of the Isolated Chicken Eye (ICE) test method. Poster presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

Truax JF, **Choksi NY**, Inhof CJ, Allen DG, Tice RR, Stokes WS. Validation status of the Isolated Rabbit Eye (IRE) test method. Poster presented at Society of Toxicology 44<sup>th</sup> Annual Meeting, New Orleans, LA, March 2005.

**Choksi NY**, Haseman JH, Allen DG, Tice RR, Stokes WS. Estimation of the underprediction rates for the in vivo rabbit dermal irritation assay. Poster presented at Society of Toxicology 43<sup>rd</sup> Annual Meeting, Baltimore, MD, March 2004.

Tice RR, **Choksi NY**, Allen DG, Haseman JH, Hill R, Lewis M, et al. Estimation of the underprediction rates for the in vivo rabbit dermal corrosion assay. Poster presented at Society of Toxicology 43<sup>rd</sup> Annual Meeting, Baltimore, MD, March 2004.

**Choksi NY**, Nix WB, Wyrick SD, Booth RG. Phenylaminotetralins activate histamine H1 receptors to stimulate dopamine synthesis in vivo in rat brain. Poster presented at the Receptor Chemistry Towards the Third Millennium - 12th Camerino-Noordwijkerhout Symposium, 1999.

**Choksi NY**, Mukherjee P, Lindroth A, Xiang Z, Wasco W, Buxbaum JD, Pasinetti GM. Cyclooxygenase (COX)-2 expression is associated with presenilin-2 induced apoptosis. Poster presented at Society for Neuroscience Annual Meeting, 1999.

Fang Y, **Choksi NY**, Parvathy S, Yamin JJ, Wasco W, Buxbaum JD. Proteins interacting with the COOH-termini of the presenilins. Poster presented at Society for Neuroscience Annual Meeting, 1999.

Lilliehook C, **Choksi NY**, Hof P, Choi EK, Zaidi NF, Wasco W, et al. Characterization of the presenilin-binding protein calsenilin. Poster presented at Society for Neuroscience Annual Meeting, 1999.

Parvathy S, **Choksi N**, Fang Y, Sabo SL, Buxbaum JD. Characterization of multipartite complexes of APP. Poster presented at Society for Neuroscience Annual Meeting, 1999.

Booth RB, Brown RL, Bucholtz ED, **Choksi NY**, Owens CE, Wyrick S.D. Phenylaminotetralins: A new class of histamine H1-type ligands that affect catecholamine synthesis and release in vitro and in vivo. Society for Neuroscience Abstracts, 24:1838, 1998.

**Choksi NY**, Wyrick SD, Booth RG. Phenylaminotetralins modulate dopamine synthesis in rat nucleus accumbens in vivo by a presynaptic H1-type receptor. Poster presented at Society for Neuroscience Annual Meeting, 1997.

**Choksi NY**, Wyrick SD, Booth RG. Modulation of brain dopamine synthesis in vivo by a putative  $\sigma$  3 agonist via a G-protein coupled receptor mechanism. Poster presented at Society for Neuroscience Annual Meeting, 1996.

**Choksi NY**, Waller CL, Booth RG. Neurotoxic and neuroprotective effects of polychlorinated biphenyls and adenosine compounds in rat brain. Presented at Society for Neuroscience Annual Meeting, San Diego, CA, November 1995.

Prioleau C, Montague DM, **Choksi NY**, Southerland SB, Lawler CP, Mailman RB. Unusual neurochemical properties of the novel antipsychotic OPC-14597 in rat striatum. Poster presented at Society for Neuroscience Annual Meeting, 1995.

**Choksi NY**, Hussain A, Myers AM, Owens CE, Harvey RD, Wyrick SD, Baldessarini RJ, Booth RG. Stimulation of brain cAMP and dopamine synthesis by adenosine A2 and  $\sigma$  3 agonists. Poster presented at Society for Neuroscience Annual Meeting, 1994.

**Choksi NY**, Hussain A, Owens CE, Myers AM, Harvey RD, Baldessarini RJ, Wyrick SD, Booth RG. Adenosine A2 and PAT-  $\sigma$  3 agonists affect adenylyl cyclase activity and dopamine synthesis. Poster presented at North Carolina Society for Neuroscience Meeting, 1994.